Our products


Portfolio of biosimilars with limited competition

Xbrane develops biosimilars on originator products where we believe we can make a significant difference in terms of improved accessibility with lower pricing. Our leading biosimilar, Xlucane™ (ranibizumab biosimilar) will save elderly people suffering from Age-related Macular Degeneration from severe vision impairment, by providing a more cost-efficient treatment than currently available.

ProductOriginal drugActive SubstancePrimary IndicationEstimated sales of original drugPatent expiry for original drugDevelopment phase
Xlucane™Lucentis®RanibizumabWet age-related macular degeneration, diabetic-related macular edema, and retinal vein occlusionSEK 32 billion 2022 (Europe) 2020 (US)Phase III
Xcimzane™Cimzia®Certolizumab pegolRheumatoid arthritis, axial spondylarthrosis, psoriasis and Crohn's diseaseSEK 19 billion 2024 (US) 2025 (Europe)Pre-clinical phase
Xdivane™Opdivo®NivolumabMelanoma, lung cancer, renal cell carcinoma, head and throat cancer, bladder and urinary tract cancerSEK 64 billion2026-2031 depending on countryPre-clinical phase
Xoncane™Oncaspar®PegaspargaseAcute lymphatic leukemia SEK 2 billion ExpiredPre-clinical phase
SpherotideDecapeptyl®TriptorelinProstate cancer, breast cancer, endometriosis and myomaSEK 4 billion ExpiredPre-clinical phase

Xlucane™


Xlucane™ is used in the treatment of wet form of Age-related Macular Degeneration (AMD), Diabetes-related Macular Edema (DME), Diabetic Retinopathy (DED) and Retinal Vein Occlusion (RVO). Overall it is estimated that all indications combined have a prevalence of over 18 million potential patients globally.  Xlucane™ will provide a more cost-efficient treatment compared to the established VEGFa inhibitors Lucentis® and Eylea® and thereby make the treatment accessible to large groups of the population globally and realize significant savings for the healthcare community. In 2020 the VEGFa inhibitor market for ophthalmic use generated sales of EUR 10.1 billion out of which Lucentis® accounted for EUR 3.1 billion.

Xbrane has completed the development of the production process for Xlucane™ on commercial scale and has demonstrated a high level of similarity compared with the originator product on the basis of a panel analysis method in accordance with guidelines from the EMA and FDA.

The confirmatory clinical equivalence phase III trial is continuing. MAA/BLA is expected to be filed in 2021.

Xbrane has signed a co-development agreement for Xlucane™ with the German generic/biosimilar company STADA. Under the agreement Xbrane is responsible for developing the product and STADA for sales and marketing. Development expenses and profits generated from sales of the product will be shared 50/50. The North-American rights for the product have been out-licensed to Bausch+Lomb.